Phase 1/2a, Single Dose Study Investigating NTLA-5001 in Subjects with Acute Myeloid Leukemia
This study will be conducted to evaluate the safety, tolerability, cellular kinetics (CK), activity, and pharmacodynamics (PD) of NTLA-5001 in participants with Acute Myeloid Leukemia (AML).
Dose Escalation: To identify dose for use in the expansion cohorts
Dose Expansion: To evaluate the safety and tolerability of NTLA-5001 in subjects with AML and lower disease burden (Arm 1) and in subjects with AML and higher disease burden (Arm 2)
-To characterize the cell kinetics (CK) of NTLA-5001 in peripheral blood
-To estimate the anti-tumor activity of NTLA-5001 in subjects with AML
-To estimate other cancer-related outcomes in subjects with AML
-To characterize subject AAV exposure
-To characterize immunologic parameters and characteristics of NTLA-5001 cells after administration in subjects with AML
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub